🔥🐔 BizChicken 🐔🔥
Companies Similar to Larimar Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Reneo Pharmaceuticals, Inc.
REN001
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.
About | About | About | Management | Directors | Contact | Contact | Careers | Careers | About | About | About
Symbol: RPHM
Recent Price: $18.20
Industry: Biotechnology
CEO: Mr. Gregory J. Flesher
Sector: Healthcare
Employees: 8
Address: 18575 Jamboree Road, Irvine, CA 92612
Phone: 619 733 3852
Last updated: 2024-12-31
Telomir Pharmaceuticals, Inc. Common Stock
TELOMIR-1
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on developing and commercializing therapies for age-related inflammatory conditions and post-chemotherapy recovery.
Symbol: TELO
Recent Price: $4.64
Industry: Biotechnology
CEO: Mr. Erez Aminov
Sector: Healthcare
Employees: 1
Address: 855 N Wolfe Street, Baltimore, null 21205
Phone: (737)-289-0835
Last updated: 2024-12-31
Travere Therapeutics, Inc.
Chenodal, Cholbam, Thiola, Sparsentan, TVT-058
Travere Therapeutics, Inc. is a biopharmaceutical company that focuses on identifying, developing, commercializing, and delivering therapies for the treatment of rare diseases. Its products include Chenodal, Cholbam, Thiola, and candidates like Sparsentan and TVT-058.
About | Leadership | About | About | About | Contact | Contact | Careers | Careers | About | News | About | About | About | About | About | About | News | Events | About | About | ESG | About | Jobs | Jobs | Careers | About | About | About | About
Symbol: TVTX
Recent Price: $17.32
Industry: Biotechnology
CEO: Dr. Eric M. Dube Ph.D.
Sector: Healthcare
Employees: 380
Address: 3611 Valley Centre Drive, San Diego, CA 92130
Phone: 888 969 7879
Leadership
- Eric Dube, Ph.D., President & Chief Executive Officer
- Chris Cline, CFA, Chief Financial Officer
- Angela Giannantonio, Senior Vice President, Human Resources
- Peter Heerma, Chief Commercial Officer
- Jula Inrig, M.D., Chief Medical Officer
- Casey Logan, Chief Business Officer
- Elizabeth Reed, J.D., Senior Vice President, General Counsel, Corporate Secretary
- William Rote, Ph.D., Senior Vice President, Research & Development
- Charlotte Smith, Senior Vice President, Public Affairs
- Gary A. Lyons, Chairman
- Roy D. Baynes, M.D., Ph.D.,
- Suzanne L. Bruhn, Ph.D.,
- Tim Coughlin, CPA,
- Jeffrey A. Meckler,
- John A. Orwin,
- Sandra E. Poole,
- Ron Squarer,
- Ruth Williams-Brinkley, FACHE,
Last updated: 2024-12-31
Aprea Therapeutics, Inc.
ATRN-119
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
Symbol: APRE
Recent Price: $3.48
Industry: Biotechnology
CEO: Dr. Oren Gilad Ph.D.
Sector: Healthcare
Employees: 7
Address: 535 Boylston St., Boston, MA 02116
Phone: 617-463-9385
Last updated: 2024-12-31
Atara Biotherapeutics, Inc.
T-cell immunotherapy treatments
Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.
About | About | About | Contact | About | Careers | Careers | About | Careers | Careers | About | About
Symbol: ATRA
Recent Price: $13.28
Industry: Biotechnology
CEO: Dr. Anhco Nguyen Ph.D.
Sector: Healthcare
Employees: 165
Address: 611 Gateway Boulevard, South San Francisco, CA 94080
Phone: 650 278 8930
Last updated: 2024-12-31
Cognition Therapeutics, Inc.
CT1812
Cognition Therapeutics is a clinical-stage biopharmaceutical company specializing in small molecule therapeutics for age-related degenerative diseases and central nervous system disorders. Its lead product, CT1812, is designed to treat Alzheimer's disease and dementia with Lewy bodies.
Symbol: CGTX
Recent Price: $0.75
Industry: Biotechnology
CEO: Ms. Lisa Ricciardi
Sector: Healthcare
Employees: 25
Address: 2500 Westchester Avenue, Purchase, NY 10577
Phone: 412 481 2210
Leadership
- Lisa Ricciardi, Chief Executive Officer
- Anthony C. Caggiano, M.D., Ph.D., Chief Medical Officer, Head of R&D
- John Doyle, Chief Financial Officer
- Anita Cornet, Head of Quality
- Theresa Devins, DrPH, Vice President, Clinical Operations
- Mary Hamby, Ph.D., Vice President, Research
- Bobby Horn, Corporate Controller
- Jennifer Iaci, Vice President, Development Operations
- Steven A. Weissman, Ph.D., Vice President and Head of CMC
- Jack A. Khattar, CEO
- Aaron Fletcher, Ph.D.,
- Brett P. Monia, Ph.D., CEO
- Ellen B. Richstone,
- Peggy Wallace,
Last updated: 2024-12-31
Intensity Therapeutics, Inc.
INT230-6
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of cancer drugs for treating solid tumors. Their lead product, INT230-6, is undergoing Phase 2 trials for various cancers and is being tested in collaborations with major pharmaceutical companies.
Symbol: INTS
Recent Price: $1.82
Industry: Biotechnology
CEO: Mr. Lewis H. Bender M.A., M.B.A., M.S.
Sector: Healthcare
Employees: 5
Address: 61 Wilton Road, Westport, CT 06880
Phone: 203 221 7381
Leadership
- Lewis H. Bender, M.S., M.A., M.B.A., Founder and CEO
- Joseph Talamo, CPA, Chief Financial Officer
- James M. Ahlers, Executive Vice President
- Brian Schwartz, MD, Executive VP, Clinical Development
- John Wesolowski, CPA, MBA, Principal Accounting Officer and Controller
- Kimberly A. Guedes, RN, MBA, Vice President of Clinical Operations
- Doranne Frano, Regulatory Affairs and Quality Control
- Daniel J. Donovan, Board Member and Chief Executive Officer
- Tom Dubin, Board Member
- Mark A. Goldberg, MD, Board Member
- Emer Leahy, Ph.D., Board Member
Last updated: 2024-12-31
Legend Biotech Corporation
LCAR-B38M
Legend Biotech Corporation is a clinical-stage biopharmaceutical company focusing on the discovery and development of novel cell therapies for oncology and other indications globally.
About | Our Story | Leadership | About | About | Contact | Careers | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Careers | About | About
Symbol: LEGN
Recent Price: $32.77
Industry: Biotechnology
CEO: Dr. Ying Huang Ph.D.
Sector: Healthcare
Employees: 2200
Address: 2101 Cottontail Lane, Somerset, NJ 08873
Phone: 732 317 5050
Leadership
- Ying Huang, Ph.D., CHIEF EXECUTIVE OFFICER
- Guowei Fang, Ph.D., CHIEF SCIENTIFIC OFFICER AND HEAD OF BUSINESS DEVELOPMENT
- Lori Macomber, CHIEF FINANCIAL OFFICER
- Mythili Koneru, M.D., Ph.D., CHIEF MEDICAL OFFICER
- Jim Pepin, GENERAL COUNSEL
- Steve Gavel, SENIOR VICE PRESIDENT, COMMERCIAL DEVELOPMENT, US & EUROPE
- Yuhong Qiu, Ph.D., SENIOR VICE PRESIDENT, GLOBAL REGULATORY AFFAIRS
- Birk Vanderweeën, SENIOR VICE PRESIDENT, GLOBAL MANUFACTURING & SUPPLY
- Alan Kick, SENIOR VICE PRESIDENT, GLOBAL QUALITY
- Doug Wallace, VICE PRESIDENT, GLOBAL OPERATIONS
- Elaine Qian, VICE PRESIDENT, GLOBAL HEAD OF HUMAN RESOURCES
- Tim Roberts, Global Compliance Officer
- Simon Wu, Senior Vice President, General Manager, Greater China
- Frank Zhang, EMBA, Ph.D., CHAIRMAN OF THE BOARD, LEGEND BIOTECH
- Sally Wang, M.S., PRESIDENT, GENSCRIPT
- Zhu Li, Ph.D., CHIEF STRATEGY OFFICER, GENSCRIPT
- Corazon (Corsee) Dating Sanders, Ph.D., CO-CHAIR OF THE BOARD OF ADVISORS, FRED HUTCH CANCER CENTER
- Darren Ji, M.D., Ph.D. and MBA, CHAIRMAN AND CEO, ELPISCIENCE BIOPHARMACEUTICALS
- Philip Yau, CHIEF FINANCIAL OFFICER. C&J CLARK
- Patrick Casey, Ph.D., SENIOR VICE DEAN OF RESEARCH, DUKE-NUS MEDICAL SCHOOL SINGAPORE AND A JAMES B. DUKE PROFESSOR OF PHARMACOLOGY AND CANCER BIOLOGY, DUKE UNIVERSITY
- Tomas J. Heyman, CEO, INTERLAKEN THERAPEUTICS
- Li Mao, M.D., CHIEF MEDICAL OFFICER, SCICLONE PHARMACEUTICALS
- Peter Salovey, Ph.D., Chris Argyris Professor of Psychology; Professor of Management, Epidemiology & Public Health, and Sociology; and President Emeritus of Yale University
- Michel Vounatsos, FORMER CEO OF BIOGEN INC.
- John Maraganore, Ph.D., FORMER CEO OF ALNYLAM PHARMACEUTICALS
Last updated: 2024-12-31
Mirum Pharmaceuticals, Inc.
LIVMARLI
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare and orphan diseases, with products like LIVMARLI and Volixibat.
Symbol: MIRM
Recent Price: $41.18
Industry: Biotechnology
CEO: Mr. Christopher Peetz
Sector: Healthcare
Employees: 294
Address: 950 Tower Lane, Foster City, CA 94404
Phone: 650 667 4085
Leadership
- Chris Peetz, Chief Executive Officer, Mirum Pharmaceuticals
- Erin Campany, Senior Vice President, Human Resources
- Eric Bjerkholt, Chief Financial Officer
- Jean-Luc Girardet, Ph.D., Senior Vice President, Technical Operations
- Vinita Kumar, Senior Vice President, Quality
- Lara Longpre, Chief Development Officer
- Joanne Quan, M.D., Chief Medical Officer
- Peter Radovich, President & Chief Operating Officer
- Paul Ross, Chief Compliance Officer
- Pamela Vig, Ph.D., Chief Scientific Officer and Head of Research
- Laura Brege, Board Member
- Patrick Heron, Managing General Partner, Frazier Healthcare Partners
- Tim Walbert, Former Chairman, President and Chief Executive Officer, Horizon Therapeutics; Sr. Advisor, Amgen
- Lon Cardon, Ph.D., FMedSci., Board Member
- William C. Fairey, Board Member
- Laurent Fischer, M.D., President & Chief Executive Officer, Adverum Biotechnologies
- Mike Grey, Chairman of the Board, Mirum Pharmaceuticals
- Saira Ramasastry, MS, MPhil, Managing Partner, Life Sciences Advisory, LLC
Last updated: 2024-12-31
Intellia Therapeutics, Inc.
NTLA-2001, NTLA-2002, NTLA-5001
Intellia Therapeutics, Inc. is a genome editing company specializing in developing therapeutics, with a focus on in vivo and ex vivo programs, including treatments for transthyretin amyloidosis, hereditary angioedema, and acute myeloid leukemia. The company also develops engineered cell therapies and offers CRISPR/Cas9 tools.
News | About | About | Contact | Careers | Culture | DEI | Careers | Careers | Careers | Culture | Jobs | Jobs | Careers | Careers | Careers | Jobs | About | About | About
Symbol: NTLA
Recent Price: $11.41
Industry: Biotechnology
CEO: Dr. John M. Leonard M.D.
Sector: Healthcare
Employees: 526
Address: 40 Erie Street, Cambridge, MA 02139
Phone: 857 285 6200
Last updated: 2024-12-31
Phio Pharmaceuticals Corp.
INTASYL therapeutic platform
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.
Symbol: PHIO
Recent Price: $1.90
Industry: Biotechnology
CEO: Mr. Robert J. Bitterman
Sector: Healthcare
Employees: 8
Address: 257 Simarano Drive, Marlborough, MA 01752
Phone: 508 767 3861
Last updated: 2024-12-31
PTC Therapeutics, Inc.
Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.
About | History | Leadership | About | Contact | Careers | Careers | Jobs | About | About | About | About
Symbol: PTCT
Recent Price: $45.77
Industry: Biotechnology
CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Sector: Healthcare
Employees: 988
Address: 100 Corporate Court, South Plainfield, NJ 07080
Phone: 908 222 7000
Leadership
- Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
- Neil Almstead, Ph.D., Chief Technical Operations Officer
- John Baird, Ph.D., Chief of Staff to the CEO
- Mark E. Boulding, Executive Vice President and Chief Legal Officer
- Lee Golden, M.D., Chief Medical Officer
- Pierre Gravier, Chief Financial Officer
- Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
- Linda Montella-Carter, Senior Vice President and Chief Information Officer
- Eric Pauwels, Chief Business Officer
- Hege Sollie-Zetlmayer, Chief Human Resources Officer
- Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
- Michael Schmertzler, Chairman
- William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
- Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
- Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
- Emma Reeve, Independent Board Director
- Mary Smith, The VENG Group
- David P. Southwell, Former CEO, TScan Therapeutics
- Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
- Alethia Young, Chief Financial Officer, Bicycle Therapeutics
- Jerome B. Zeldis, M.D., Ph.D., Independent Board Director
Last updated: 2024-12-31
Rocket Pharmaceuticals, Inc.
Gene Therapies
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.
Symbol: RCKT
Recent Price: $12.03
Industry: Biotechnology
CEO: Dr. Gaurav D. Shah M.D.
Sector: Healthcare
Employees: 268
Address: 9 Cedarbrook Drive, Cranbury, NJ 08512
Phone: 609 659 8001
Last updated: 2024-12-31
Cartesian Therapeutics, Inc.
SEL-302, SEL-212
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.
Symbol: RNAC
Recent Price: $18.76
Industry: Biotechnology
CEO: Dr. Carsten Brunn Ph.D.
Sector: Healthcare
Employees: 37
Address: 65 Grove Street, Watertown, MA 02472
Phone: 617 923 1400
Last updated: 2024-12-31
Syros Pharmaceuticals, Inc.
Tamibarotene
Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control medicines. Key products include Tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, and SY-5609 for advanced solid tumors.
About | Leadership | Directors | About | Contact | Careers | Vision/Values | DEI | Careers | About | About
Symbol: SYRS
Recent Price: $0.25
Industry: Biotechnology
CEO: Mr. Conley Chee
Sector: Healthcare
Employees: 68
Address: 35 CambridgePark Drive, Cambridge, MA 02140
Phone: 617 744 1340
Leadership
- Conley Chee, President and Chief Executive Officer
- Jason Haas, Chief Financial Officer
- Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
- Lisa Roberts, VP Human Resources
- David A. Roth, M.D., Chief Medical Officer
- Kristin Stephens, Chief Development Officer
Last updated: 2024-12-31
Protara Therapeutics, Inc.
N/A
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
No tags available.
Symbol: TARA
Recent Price: $5.28
Industry: Biotechnology
CEO: Mr. Jesse Shefferman
Sector: Healthcare
Employees: 26
Address: 345 Park Avenue South, New York, NY 10010
Phone: 646 844 0337
Last updated: 2024-12-31
Xilio Therapeutics, Inc.
XTX101
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.
Symbol: XLO
Recent Price: $0.97
Industry: Biotechnology
CEO: Dr. Rene Russo BCPS, Pharm.D.
Sector: Healthcare
Employees: 73
Address: 828 Winter Street, Waltham, MA 02451
Phone: 617 430 4680
Last updated: 2024-12-31
Cadrenal Therapeutics, Inc. Common Stock
Tecarfarin
Cadrenal Therapeutics, Inc. is a clinical development biopharmaceutical company focusing on novel therapies for preventing systemic thromboembolism in patients with specific health conditions, headquartered in Ponte Vedra, Florida.
Symbol: CVKD
Recent Price: $14.23
Industry: Biotechnology
CEO: Mr. Quang X. Pham
Sector: Healthcare
Employees: 4
Address: 822 A1A North, Ponte Vedra, FL 32082
Phone: 904 300 0701
Last updated: 2024-12-31
Ionis Pharmaceuticals, Inc.
RNA-targeted therapeutics
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.
About | About | About | DEI | DEI | DEI | DEI | Contact | Contact | Careers | Careers | Careers | Careers | Careers | Careers | About | About | News | About | About | ESG | DEI | DEI | About | About | About | Management | About | About | About | About | About | About | About | About | About | About | Careers | Careers | Careers | Careers | Careers | ESG | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About | About | About | About | About | About | Jobs | About | About
Symbol: IONS
Recent Price: $34.92
Industry: Biotechnology
CEO: Dr. Brett P. Monia Ph.D.
Sector: Healthcare
Employees: 927
Address: 2855 Gazelle Court, Carlsbad, CA 92010
Phone: 760 931 9200
Last updated: 2024-12-31
Larimar Therapeutics, Inc.
CTI-1601
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for rare diseases using a novel cell penetrating peptide technology platform. Their lead product candidate, CTI-1601, is undergoing Phase 1 clinical trials to treat Friedreich's ataxia.
About | Leadership | Directors | About | Contact | Contact | Careers | Careers | About | About | About | Careers
Symbol: LRMR
Recent Price: $3.91
Industry: Biotechnology
CEO: Dr. Carole S. Ben-Maimon M.D.
Sector: Healthcare
Employees: 42
Address: Three Bala Plaza East, Bala Cynwyd, PA 19004
Phone: 844 511 9056
Leadership
- Carole Ben-Maimon, MD, President and Chief Executive Officer
- Gopi Shankar, PhD, MBA, FAAPS, Chief Development Officer
- Rusty Clayton, DO, Chief Medical Officer
- Michael Celano, CHIEF FINANCIAL OFFICER
- John Berman, Vice President of Finance and Administration
- Jennifer Johansson, Vice President, Legal and Compliance
- Keith E. Lynch, Jr., Vice President, CMC Technical Operations
- Noreen Scherer, Vice President of Clinical Operations
- Francis Michael Conway, CPA, VICE PRESIDENT AND CONTROLLER
- Mohamed Hamdani, Vice President, Statistics and Quantitative Sciences
- Adrienne Clements-Egan, Ph.D., Vice President, Bioanalytics and Developability
- Frank Nazzario, RPh, Vice President, Commercial
- Joseph Truitt, BOARD CHAIR
- Tom Hamilton,
- Jonathan Leff,
- Frank E. Thomas,
- Jeffrey Sherman, MD,
- ,
Last updated: 2024-12-31